The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

US stock markets finished flat on Monday after erasing earlier losses by the close, with investors treading cautiously ahead of a busy week for corporate earnings and economic data.

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. and its board of directors concerning the proposed acquisition of the company by Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire U.S.-based SpringWorks Therapeutics for approximately ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

Looking at drug momentum, supply stability, and DTC growth, here’s what we think of Eli Lilly’s stock.

Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...